➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Tralokinumab

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Tralokinumab?

Tralokinumab is an investigational drug.

There have been 10 clinical trials for Tralokinumab. The most recent clinical trial was a Phase 2 trial, which was initiated on June 19th 2018.

The most common disease conditions in clinical trials are Eczema, Dermatitis, Atopic, and Dermatitis. The leading clinical trial sponsors are LEO Pharma, Emma.Guttman, and AstraZeneca.

There are seven US patents protecting this investigational drug and seventy-six international patents.

Recent Clinical Trials for Tralokinumab
Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis Who Are Not Adequately Controlled With or Have Contraindications to Oral Cyclosporine ALEO PharmaPhase 3
Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTENDLEO PharmaPhase 3
Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)LEO PharmaPhase 2

See all Tralokinumab clinical trials

Clinical Trial Summary for Tralokinumab

Top disease conditions for Tralokinumab
Top clinical trial sponsors for Tralokinumab

See all Tralokinumab clinical trials

US Patents for Tralokinumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tralokinumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Tralokinumab   Start Trial Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY)   Start Trial
Tralokinumab   Start Trial Compositions and methods for treating fibrotic disease eFFECTOR Therapeutics Inc. (San Diego, CA)   Start Trial
Tralokinumab   Start Trial Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA)   Start Trial
Tralokinumab   Start Trial Meditopes and meditope-binding antibodies and uses thereof City of Hope (Duarte, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tralokinumab

Drugname Country Document Number Estimated Expiration Related US Patent
Tralokinumab Australia 2013220749 2032-02-15   Start Trial
Tralokinumab Brazil 112014019627 2032-02-15   Start Trial
Tralokinumab Canada 2862476 2032-02-15   Start Trial
Tralokinumab China 104114705 2032-02-15   Start Trial
Tralokinumab China 108570468 2032-02-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.